|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Coronary artery disease is the most common cause of death globally and is linked to a number of risk factors including serum low density lipoprotein, high density lipoprotein, triglycerides and lipoprotein(a).
|
29713054 |
2018 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In elder CHD patients, levels of the total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterin (LDL-C) were significantly higher than the normal reference, and comparison with the control group also showed significant increases (<i>p</i> < 0.01); average levels of the high-density lipoprotein cholesterin (HDL-C), phospholipid (PL), lipoprotein a [LP (a)] and free fatty acid were in the range of normal reference.
|
30591805 |
2018 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis identified 7 single nucleotide polymorphisms at a genome-wide level of significance within the LPA/PLG locus associated with CHD events on statin treatment.
|
29703846 |
2018 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus.
|
30030022 |
2018 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disorders including coronary heart disease and calcific aortic valve stenosis.
|
29852400 |
2018 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Though lipoprotein (a) (Lp (a)) has been considered as a risk factor for coronary artery disease, there is a lack of cutoff values of Lp (a) for Chinese Han ethnicity.
|
29883631 |
2018 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for coronary heart disease (CHD) and calcific aortic valve stenosis (CAVS).
|
29262744 |
2018 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] has been classified as the most prevalent genetic risk factor for coronary artery disease and aortic valve stenosis.
|
30087087 |
2018 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein (a) as a Marker for Predicting the Presence and Severity of Coronary Artery Disease in Untreated Chinese Patients Undergoing Coronary Angiography.
|
29773088 |
2018 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The median follow-up was 9·9 years.Increased severity of coronary heart disease was associated with lipoprotein(a) concentrations in plasma in the highest tertile (adjusted hazard radio [HR] 1·44, 95% CI 1·14-1·83) and the presence of either LPA SNP (1·88, 1·40-2·53).
|
28566218 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein (a) [Lp(a)] is an independent but moderate, predictor for coronary heart disease (CHD) prevalence and severity.
|
28078997 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a)[Lp(a)] is a risk factor for coronary heart diseases.
|
28192139 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, we compared phenotypic versus genotypic ORs to estimate whether apolipoprotein(a) isoform size, lipoprotein(a) concentration, or both were causally associated with coronary heart disease.
|
28408323 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) as a predictor of poor collateral circulation in patients with chronic stable coronary heart disease.
|
28700032 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Evidence from genetic studies suggests that besides lowering low-density lipoprotein cholesterol, pharmacological reduction of triglyceride-rich lipoproteins, or lipoprotein(a) will reduce risk for coronary heart disease.
|
28528455 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interaction Between Vitamin D and Lipoprotein (a) on the Presence and Extent of Coronary Heart Disease.
|
28238617 |
2017 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The association of elevated lipoprotein(a) (Lp(a)) levels and the incidence of cardiovascular disease, especially coronary heart disease and ischemic stroke, is well established.
|
27856951 |
2017 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
|
28351002 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease.
|
29246959 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease.
|
28883849 |
2017 |
|
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Long-Term Prognostic Value of Lipoprotein(a) in Symptomatic Patients With Nonobstructive Coronary Artery Disease.
|
28139221 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) (Lp[a]) is proatherosclerotic and prothrombotic, causally related to coronary disease, and associated with other cardiovascular diseases.
|
29246963 |
2017 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In addition, compared with the placebo, taking flaxseed oil supplements down-regulated gene expression levels of lipoprotein(a) [LP(a)] (P = 0.001), interleukin-1 (IL-1) (P = 0.001) and tumor necrosis factor alpha (TNF-α) (P = 0.02) in PBMC of diabetic patients with CHD.
|
28916975 |
2017 |
|
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
|
28753643 |
2017 |
|
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to investigate CHD or cardiovascular disease (CVD) risk scores with cholesterol levels of six fractionated lipoprotein classes {high-density lipoprotein [HDL], low-density lipoprotein [LDL], IDL, VLDL, CM including CM remnant, and lipoprotein (a) [Lp (a)]} in Japanese healthy men.
|
28025448 |
2017 |